|
|
| |
| The restless boy may show up again at 70 |
| Some boys never sat still in school. Many grew up without a name for it. Today doctors call it attention deficit hyperactivity disorder. It’s lifelong wiring that lets focus slip and restlessness win. Now a team at the University of Pittsburgh has checked what it means after 50. Tharick Pascoal’s group pulled health records and genes for more than 187,000 adults. Of those with the condition, 6.7% went on to dementia or memory trouble. Of the rest, 3.4% did. After the team adjusted for age and other illnesses, the risk ran more than four times higher. |
| Let me explain the obvious doubt first. You might think the label was just early dementia in disguise. Lost keys and a wandering mind look alike. But the link held when eight years or more sat between the two diagnoses. And people with the most genes for the condition had 35% more dementia. That points to something built in, not a mix-up. |
| So why would it matter decades later? Nobody knows yet. One idea is reserve. Think of a boat that has always taken on a little water. It floats fine for years. But it has less room to spare when the storm comes. The condition also travels with poor sleep, smoking and heart trouble. Each of those wears on the brain over time. |
| |
Israel saw the same thing in 2023. A study there followed about 109,000 adults. Those with the condition had close to three times the dementia risk. But people treated with stimulant medicine showed no clear rise. That’s one study. It can’t prove the pills protect. |
|
| I could be wrong about where this leads. Records studies can’t show cause. Some cases get missed, and some get labeled too easily. Still, two big studies in two countries now point the same way. I believe the signal is real. |
| Has focus fought you all your life? Tell your doctor. Then guard what you can move. I urge you to protect your sleep, watch your blood pressure and leave the cigarettes alone. |
| University of Pittsburgh · 187,000+ adults over 50 · October 2026 |
|
|
|
|
| |
| Get your hands in the dirt this fall |
| Gardening looks like a chore. Your brain may count it as a workout. You bend, lift and dig. You plan where each plant goes. And you do it outside, in real daylight. |
| The long view comes from Scotland. Janie Corley at the University of Edinburgh studied 467 people born in 1921. They took the same thinking test at 11 and again at 79. The gardeners gained more over their lives. They kept that lead up to age 90. The edge was small, and it can’t prove cause. |
| A trial in Denver went a step further. It gave 291 non-gardeners either a free plot or a year’s wait. The gardeners moved about 42 more minutes a week. Their stress and worry dropped. The most stressed people dropped the most. |
| October is bulb-planting month. So start there. |
| The Protocol |
| When |
| Two or three mornings a week, while the ground is still soft |
| Duration |
| 30 to 45 minutes a session, through the end of the season |
| Rules |
| Do real work: dig, rake, plant, haul. Sketch one bed on paper before you start. Kneel on a pad and lift with your legs. No yard? A balcony box or a shared town plot counts. |
| |
| Notice how you sleep that night and how calm you feel. Wear gloves, and clean any cut well, because soil can carry tetanus. I urge you to try it. |
|
|
|
|
|
|
|
| After a dementia diagnosis, extra weight went with longer life |
| The usual weight advice flips here. Columbia and New York University researchers followed 4,523 Americans who developed dementia. Compared with normal weight, being overweight went with a 16% lower risk of death. Moderate obesity went with 27% lower. Dementia often dulls appetite and burns extra energy. Weight can start sliding up to ten years before diagnosis. The authors say no one should try to gain. But if a parent with dementia starts losing weight, keep the meals coming. |
| Columbia Mailman School · Journal of Alzheimer’s Disease · October 2026 |
|
|
| A nerve zap after practice made skills stick |
| Timing mattered most here. Ko Matsui’s team at Tohoku University trained mice on a simple eye-tracking task. After each session, they gently zapped the vagus nerve in the neck. That’s the long nerve linking the brain to the gut and heart. The zaps did nothing the same day. But on later days, the mice learned better. Each zap set off slow waves of blood flow in the brain’s timing center. A vagus stimulator is already cleared in America for arm rehab after stroke. It’s mice for now. |
| Tohoku University · iScience · August 2026 |
|
|
| A gut-made compound tracked with faster memory loss |
| Your gut may make a risky compound. Some bacteria there produce one called imidazole propionate. Barbara Bendlin and Federico Rey at the University of Wisconsin–Madison measured it in about 1,200 people. Higher blood levels went with more Alzheimer’s protein signs and faster decline on memory tests. In mice, the compound pushed that protein buildup along. The bacteria make it from a building block found in many foods. So there’s no simple diet fix yet. |
| University of Wisconsin–Madison · Nature Communications · 2026 |
|
|
|
|
| |
| This week reads like a scorecard. One drug passed its big test. One failed after years of hope. And one is only now walking to the starting gate. You learn from all three. A clean miss tells scientists where not to dig. |
|
| Shortening the stiff, slow hours of Parkinson’s without touching dopamine |
| Cerevance tested a once-daily pill called solengepras. It works on a different switch in the brain’s movement circuit, not on dopamine. The Phase 3 trial is the last stage before approval. It enrolled 341 people already on standard medicine. Over 12 weeks, the higher dose cut daily “off” time by about 37 minutes more than placebo. “Off” time means the hours when the old pills wear thin. The gain showed by week two. Headache, nausea and poor sleep were a little more common. The company will now talk with American regulators about filing. |
| Phase 3 · results October 7, 2026 |
|
|
| Calming an overactive Parkinson’s gene did not slow the disease |
| Biogen and Denali bet years on BIIB122. The pill blocks an enzyme made by a gene tied to Parkinson’s. Their Phase 2b trial, the mid-stage test, enrolled 648 people within two years of diagnosis. Some took it for close to three years. The drug hit its target hard, cutting a blood marker by more than 90%. But worsening came just as fast as on placebo. Full results came out this week at the world movement-disorders meeting in Seoul. The companies have stopped work in typical Parkinson’s. A smaller trial goes on in people who carry the gene change. |
| Phase 2b · full data October 2026 · gene-carrier trial reads out 2027 |
|
|
| Turning down brain inflammation with pills already tried in people |
| The brain’s immune cells carry a danger sensor. When cells die nearby, it fires and floods the area with inflammation. Nicholas Barnes at the University of Birmingham tested blockers of that sensor on living human brain tissue saved from surgery. The blockers cut the inflammatory flood. These drugs already reach the brain, and some have been tested in people for other conditions. That could save years. The team now plans trials in Alzheimer’s, Parkinson’s and head injury. |
| Lab stage · human trials being planned · Brain, 2026 |
|
|
